Akero Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 53.34 million compared to USD 25.83 million a year ago. Basic loss per share from continuing operations was USD 0.9 compared to USD 0.55 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.19 USD | +3.45% |
|
-4.19% | -4.97% |
Jul. 01 | Akero Therapeutics, Inc.(NasdaqGS:AKRO) added to Russell Small Cap Comp Value Index | CI |
Jul. 01 | Akero Therapeutics, Inc.(NasdaqGS:AKRO) added to Russell 3000 Value Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.97% | 1.53B | |
+18.43% | 124B | |
+19.81% | 114B | |
-23.74% | 19.42B | |
-18.14% | 16.2B | |
-19.97% | 15.31B | |
-49.33% | 14.19B | |
+57.08% | 14.32B | |
+7.95% | 14.31B | |
+126.04% | 11.29B |
- Stock Market
- Equities
- AKRO Stock
- News Akero Therapeutics, Inc.
- Akero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024